DOSAGE INDEX / SINGLE
Bronchogen
Research, reported schedules and supply planning.
Bronchogen research includes a rat model of obstructive lung injury and experiments examining bronchial epithelial biology. The animal work assessed tissue remodeling, inflammation and local immune markers. A separate cell-culture study investigated gene expression and protein synthesis in bronchial epithelial cells. These are preclinical findings, including when the cultured cells are human-derived; they do not establish clinical benefit, a human injection route or a human dosing schedule.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 1 or 2 mg per day in separate examples
- Frequency
- Once daily
- Cycle / observation period
- Separate 10-day and 20-day examples
- Route / research model
- Human route not established by the source
The source identifies these as community descriptions, not a validated clinical regimen or a progression between doses.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 20 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Bronchogen research includes a rat model of obstructive lung injury and experiments examining bronchial epithelial biology. The animal work assessed tissue remodeling, inflammation and local immune markers. A separate cell-culture study investigated gene expression and protein synthesis in bronchial epithelial cells. These are preclinical findings, including when the cultured cells are human-derived; they do not establish clinical benefit, a human injection route or a human dosing schedule. [1] [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 8 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Rat obstructive-lung model
- Bronchial epithelial cell-culture study
- Linkova et al., 2018, PMID 30199201 – Rat chronic obstructive pulmonary disease model examining peptide-related molecular markers.Further reading · Listed in reference bibliography.
- Fedoreyeva et al., 2011, PMID 22117547 – Cell and biochemical study identifying Bronchogen as AEDL and examining nuclear localization and DNA interactions.Further reading · Listed in reference bibliography.
- Khavinson et al., 2021, PMID 34834147 – Systematic review of short-peptide regulation of gene expression and the supporting model evidence.Further reading · Listed in reference bibliography.
- Khavinson et al., 2022, PMID 35887081 – Review of proposed transport mechanisms for biologically active ultrashort peptides.Further reading · Listed in reference bibliography.
- U.S. FDA, Clinical Pharmacology Considerations for Peptide Drug Products – Regulatory guidance describing evidence expectations for peptide drug development.Regulatory / product information · Listed in reference bibliography.
- European Medicines Agency, Development and Manufacture of Synthetic Peptides – Scientific guideline addressing identity, manufacture, quality, and impurity control for synthetic peptides.Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.